Literature DB >> 8354302

Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine.

A L Barry1, M A Pfaller, P C Fuchs, F C Tenover, L B Reller, S D Allen, D J Hardy, E H Gerlach.   

Abstract

Studies with fosfomycin tromethamine disks containing 200 micrograms of fosfomycin and 50 micrograms of glucose-6-phosphate confirmed the following zone diameter criteria for the NCCLS method: < or = 12 mm for resistant (MIC > or = 256 micrograms/ml), 13-15 mm for intermediate (MIC 128 micrograms/ml) and > or = 16 mm for susceptible (MIC < or = 64 micrograms/ml). Additional studies defined acceptable MIC and zone diameter ranges for the following quality control strains: Escherichia coli ATCC 25922, MIC 0.5 to 4.0 micrograms/ml, zone diameter 23 to 29 mm; Staphylococcus aureus ATCC 25923, zone diameter 26 to 32 mm; Pseudomonas aeruginosa ATCC 27813, MIC 2.0 to 8.0 micrograms/ml; and Enterococcus faecalis, ATCC 29212, MIC 16 to 64 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354302     DOI: 10.1007/bf01964433

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Factors influencing the activity of the trometamol salt of fosfomycin.

Authors:  D Greenwood; A Jones; A Eley
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

2.  International collaborative study on standardization of bacterial sensitivity to fosfomycin.

Authors:  J M Andrews; F Baquero; J M Beltran; E Canton; F Crokaert; M Gobernado; R Gomez-Ius; E Loza; M Navarro; T Olay
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

3.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

4.  In vitro susceptibility testing procedures for fosfomycin tromethamine.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

5.  The trometamol salt of fosfomycin: microbiological evaluation.

Authors:  D Greenwood; S Coyle; J Andrew
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

6.  Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults.

Authors:  F Borsa; A Leroy; J P Fillastre; M Godin; B Moulin
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

  6 in total
  5 in total

Review 1.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Susceptibility testing quality control studies with fosfomycin tromethamine.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

3.  Evaluation of a new chromogenic medium, chromID OXA-48, for recovery of carbapenemase-producing Enterobacteriaceae from patients at a university hospital in Turkey.

Authors:  P Zarakolu; K M Day; H E Sidjabat; W Kamolvit; C V Lanyon; S P Cummings; D L Paterson; M Akova; J D Perry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-12       Impact factor: 3.267

4.  Antimicrobial susceptibility patterns of some recently established coryneform bacteria.

Authors:  G Funke; V Pünter; A von Graevenitz
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

5.  Fosfomycin Addition to Poly(D,L-Lactide) Coating Does Not Affect Prophylaxis Efficacy in Rat Implant-Related Infection Model, But That of Gentamicin Does.

Authors:  Anil Gulcu; Alp Akman; Ahmet Fahir Demirkan; Ali Cagdas Yorukoglu; Ilknur Kaleli; Ferda Bir
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.